Sebtembar 1 waa bilawga bisha lymphoma laga bilaabo maanta 2 kale oo dawooyin cusub ayaa lagu daray PBS oo loogu talagalay bukaannada lymfoma.
Wasiirka Caafimaadka ee Federaalka Greg Hunt ayaa dhawaan ku dhawaaqay in laga bilaabo 1da Sebtembar, bukaanada Australiyaanka ah ee u qalma ee qaba dib-u-soo-kabashada / dib-u-celinta asaasiga ah ee B-cell lymphoma (PMBCL) iyo soo noqoshada / dib u soo noqoshada Chronic Lymphocytic Leukemia (CLL) iyo Small Lymphocytic lymphoma (SLL) ay yeelan doonaan cusub. Ikhtiyaarada daawaynta ee laga heli karo PBS.
PMBCL waa nooc-hoosaad aad dhif u ah lymfoma oo bukaannadu hadda way awoodaan inay galaan keytruda haddii ay ku soo noqdeen daawayntii hore ama ay ka biyo diideen daawaynta. KEYTRUDA (Pembrolizumab) waa daawo difaac difaac ah oo awood u siinaysa habka difaaca jidhku inuu la dagaallamo lymphoma.
Calquence (Acalabrutinib) waxa kale oo laga heli doonaa PBS bukaanada Australiyaanka ah ee u qalma ee qaba Leukemia Chronic Lymphocytic Leukemia iyo Lymphoma Yaryar ee Lymphocytic. Noocyadan hoose ee lymfoma waxaa loo tixgaliyaa inay yihiin kansar dabadheeraad ah maadaama uusan waligiis tagin laakiin Calquence waxay siisaa bukaanada xaqa u leh ikhtiyaar daawaynta dheeraadka ah.
Lymphoma Australia waxay jeclaan lahayd inay u mahadceliso dhammaan bukaannada iyo xubnaha kale ee bulshada ee naga caawiyay soo gudbinta PBAC si ay daawayntan cusub u noqdaan kuwo loo ogolaaday dhammaan bukaannada xaqa u leh.
Wixii macluumaad dheeraad ah iyo faallooyinka warbaahinta, fadlan kala xidhiidh madaxa Lymphoma Australia Sharon Winton 0431 483 204.
